Rizwan Haq

14.8k total citations · 3 hit papers
60 papers, 3.0k citations indexed

About

Rizwan Haq is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Rizwan Haq has authored 60 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 30 papers in Oncology and 14 papers in Immunology. Recurrent topics in Rizwan Haq's work include Melanoma and MAPK Pathways (16 papers), Immunotherapy and Immune Responses (12 papers) and Cancer Immunotherapy and Biomarkers (12 papers). Rizwan Haq is often cited by papers focused on Melanoma and MAPK Pathways (16 papers), Immunotherapy and Immune Responses (12 papers) and Cancer Immunotherapy and Biomarkers (12 papers). Rizwan Haq collaborates with scholars based in United States, Canada and Japan. Rizwan Haq's co-authors include David E. Fisher, Jennifer A. Wargo, Dennie T. Frederick, Brent W. Zanke, Hans R. Widlund, David M. Miller, Nicholas Macedo, Howard L. Kaufman, Jun S. Song and Satoru Yokoyama and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Physical Review Letters and Journal of Biological Chemistry.

In The Last Decade

Rizwan Haq

58 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF

2013 610 citations Rizwan Haq, Dennie T. Frederick et al. profile →
A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors

2014 357 citations David J. Konieczkowski, Cory M. Johannessen et al. Cancer Discovery profile →
Clinical landscape of oncolytic virus research in 2020

2020 242 citations Rizwan Haq et al. Journal for ImmunoTherapy of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rizwan Haq United States	24	1.8k	1.2k	593	462	398	60	3.0k
Jia‐Ren Lin United States	27	2.0k 1.1×	689 0.6×	457 0.8×	363 0.8×	449 1.1×	56	3.0k
Stephan M. Feller United Kingdom	39	2.9k 1.6×	837 0.7×	836 1.4×	375 0.8×	822 2.1×	104	4.5k
Olga Potapova United States	26	2.4k 1.3×	815 0.7×	275 0.5×	554 1.2×	268 0.7×	42	3.2k
Helmut Schaider Australia	31	1.5k 0.8×	1.1k 0.9×	731 1.2×	353 0.8×	250 0.6×	82	2.9k
Yusuke Okuno Japan	30	1.5k 0.8×	494 0.4×	505 0.9×	277 0.6×	255 0.6×	168	3.1k
John Jeffers United Kingdom	29	2.4k 1.4×	1.0k 0.8×	481 0.8×	389 0.8×	294 0.7×	114	5.0k
Vincent L. Giranda United States	40	2.5k 1.4×	2.1k 1.8×	361 0.6×	552 1.2×	291 0.7×	115	4.4k
Zhenming Zhao United States	13	3.0k 1.7×	1.1k 0.9×	204 0.3×	490 1.1×	444 1.1×	16	3.7k
Andrew G. Stephen United States	32	2.8k 1.5×	681 0.6×	251 0.4×	489 1.1×	406 1.0×	92	3.6k
Omid Vafa United States	19	2.0k 1.1×	758 0.6×	671 1.1×	373 0.8×	324 0.8×	28	3.3k

Countries citing papers authored by Rizwan Haq

Since Specialization

Citations

This map shows the geographic impact of Rizwan Haq's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rizwan Haq with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rizwan Haq more than expected).

Fields of papers citing papers by Rizwan Haq

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rizwan Haq. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rizwan Haq. The network helps show where Rizwan Haq may publish in the future.

Co-authorship network of co-authors of Rizwan Haq

This figure shows the co-authorship network connecting the top 25 collaborators of Rizwan Haq. A scholar is included among the top collaborators of Rizwan Haq based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rizwan Haq. Rizwan Haq is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Haq, Rizwan, et al.. (2025). Severity and progression of dermatologic adverse events associated with tebentafusp: A retrospective multicenter cohort study. Journal of the American Academy of Dermatology. 93(4). 1116–1118. 1 indexed citations

Butler, Marcus O., Ryan Weight, Rizwan Haq, et al.. (2024). 1139TiP IDE196 (darovasertib) in combination with crizotinib versus investigator’s choice of treatment as first-line therapy in HLA-A2 negative metastatic uveal melanoma. Annals of Oncology. 35. S747–S747. 2 indexed citations

Buchbinder, Elizabeth I., Justine V. Cohen, Giuseppe Tarantino, et al.. (2024). A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma. Cancer Research Communications. 4(5). 1321–1327. 7 indexed citations

Giobbie‐Hurder, Anita, Miklos C. Fogarasi, Patrick A. Ott, et al.. (2024). Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab. Journal for ImmunoTherapy of Cancer. 12(8). e009061–e009061. 5 indexed citations

Khaddour, Karam, Rizwan Haq, Elizabeth I. Buchbinder, et al.. (2024). Targeting RAF1 gene fusions with MEK inhibition in metastatic melanoma. The Oncologist. 30(3).

Conway, Jake R., Jett Crowdis, Brendan Reardon, et al.. (2024). Somatic structural variants drive distinct modes of oncogenesis in melanoma. Journal of Clinical Investigation. 134(13).

Cattaneo, Giulia, Jingyu Jia, Luke Maggs, et al.. (2023). 317 B7-H3-targeted CAR T cell with an inducible caspase 9 suicide gene effectively eradicates uveal melanoma liver metastases. SHILAP Revista de lepidopterología. A360–A360. 1 indexed citations

Lutzky, Jose, Ryan J. Sullivan, Justine V. Cohen, et al.. (2023). Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma. Journal of Cancer Research and Clinical Oncology. 149(9). 6059–6066. 14 indexed citations

Montero, Joan & Rizwan Haq. (2022). Adapted to Survive: Targeting Cancer Cells with BH3 Mimetics. Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona). 37 indexed citations

10.

Wei, Alexander Z., Michael P. Manos, Jasmine H. Francis, et al.. (2022). Characterizing metastatic uveal melanoma patients who develop symptomatic brain metastases. Frontiers in Oncology. 12. 961517–961517. 6 indexed citations

11.

Ott, Patrick A., Kathleen L. Pfaff, Evisa Gjini, et al.. (2021). Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial. Journal for ImmunoTherapy of Cancer. 9(11). e003318–e003318. 12 indexed citations

12.

Conway, Jake R., Felix Dietlein, Amaro Taylor‐Weiner, et al.. (2020). Integrated molecular drivers coordinate biological and clinical states in melanoma. Nature Genetics. 52(12). 1373–1383. 28 indexed citations

13.

Wang, Daniel, Zeynep Eroglu, Alpaslan Özgün, et al.. (2017). Clinical Features of Acquired Resistance to Anti–PD-1 Therapy in Advanced Melanoma. Cancer Immunology Research. 5(5). 357–362. 35 indexed citations

14.

Gee, Michael S., Arezou A. Ghazani, Rizwan Haq, et al.. (2016). Point of care assessment of melanoma tumor signaling and metastatic burden from μNMR analysis of tumor fine needle aspirates and peripheral blood. Nanomedicine Nanotechnology Biology and Medicine. 13(3). 821–828. 7 indexed citations

15.

Lauss, Martin, Rizwan Haq, Helena Cirenajwis, et al.. (2015). Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation. Journal of Investigative Dermatology. 135(7). 1820–1828. 42 indexed citations

16.

Konieczkowski, David J., Cory M. Johannessen, Omar O. Abudayyeh, et al.. (2014). A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors. Cancer Discovery. 4(7). 816–827. 357 indexed citations breakdown →

17.

McGill, Gaël, Rizwan Haq, Emi K. Nishimura, & David E. Fisher. (2006). c-Met Expression Is Regulated by Mitf in the Melanocyte Lineage. Journal of Biological Chemistry. 281(15). 10365–10373. 138 indexed citations

18.

Ho, Jenny, Jamil Dierov, Bryan K. Beattie, et al.. (2002). TEL-JAK2 constitutively activates the extracellular signal-regulated kinase (ERK), stress-activated protein/Jun kinase (SAPK/JNK), and p38 signaling pathways.. Blood. 100(4). 1438–48. 32 indexed citations

19.

Haq, Rizwan, et al.. (2001). NKIATRE Is a Novel Conserved cdc2-Related Kinase. Genomics. 71(2). 131–141. 10 indexed citations

20.

Haq, Rizwan & Brent W. Zanke. (1998). Inhibition of apoptotic signaling pathways in cancer cells as a mechanism of chemotherapy resistance. Cancer and Metastasis Reviews. 17(2). 233–239. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact